SELUTION SLR PTCA Drug Eluting Balloon
The SELUTION SLR™ Drug Eluting Balloon (DEB) is the latest generation of drug-eluting balloon technology designed to Go Beyond Metal and deliver consistent and predictable drug release as best-in-class drug-eluting stents.
The New Paradigm for Coronary Interventions
Breakthrough technology to deliver sustained limus release up to 90 days.
CELL ADHERENT TECHNOLOGY
CELL ADHERENT TECHNOLOGY (CAT)™ facilitates drug uptake and retention, in the tissue, with a minimal drug loss during the procedure while providing excellent deliverability.
MICRORESERVOIRS
MicroReservoirs achieve a consistent and predictable drug release, at a therapeutic level, comparable to the latest generation drug-eluting stent technology
SIZE MATRIX
SELUTION SLR DEB offers a broader portfolio to extend treatment options for coronary artery disease
The SELUTION DeNovo Study1
A prospective randomized, multi-center, international, single-blind clinical trial comparing the SELUTION SLR DEB Strategy Versus Drug-Eluting Stent (DES) Strategy.
- Landmark randomized trial for coronary de-novo lesions, all-comers enrollment
- Designed to evaluate non-inferiority at 1 and 5 years and possible superiority at 5 years
- Primary Endpoints: Target Vessel Failure at 1 year and 5 years
ADVANCING DRUG-ELUTING BALLOON EDUCATION
Empowering healthcare practitioners through professional education initiatives including these webinars:
- DEB in Bifurcations: Simplifying the Complex
- DCB PCI in clinical practice: negotiating the learning curve
- Minimal-metal PCI: a drug-coated balloon philosophy combined with selective lesion stenting where necessary - the hybrid approach
- From Access to Closure through Treatment: How to Maximize Outcomes while Minimizing Impact
- Go beyond metal: exploring drug-eluting balloon technology in de novo coronary lesions – EuroPCR 2024
SELUTION SLR DEB Cases
Complex PCI: SELUTION SLR™ DEB in long and calcified lesions
Learn More
Tailoring PCI: From full metal jacket to waistcoat
Learn MoreDr. Simon Eccleshall, UK
SELUTION DeNovo Study - the first 1,000 patients
Prof. Cuculi, Heart Centre, Lucerne, Switzerland
Towards a new era with less metal in patients' coronary arteries
Dr. Rissanen, North Karelia Central Hospital, Joensuu, Finland
Vessel preparation as the key success factor
Dr. Neylon, Jacques Cartier Private Hospital, Massy, France
Keeping bifurcations as simple as possible with less metal
Dr. Mashayekhi, Heartcenter Lahr, Germany
Reducing stent length in CTO with a hybrid approach
Resources
Customer Service and Ordering Information
For country-specific contact details, please see this page.